- United States
- /
- Life Sciences
- /
- NasdaqCM:BLFS
Discovering Bank First And 2 More Stocks That May Be Trading Below Their Estimated Value
As the U.S. stock market navigates through the complexities of a government shutdown and fluctuating economic indicators, major indices like the Dow Jones and S&P 500 have shown resilience with recent gains. In this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows In The United States
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Udemy (UDMY) | $6.76 | $13.43 | 49.7% |
| SLM (SLM) | $27.55 | $53.65 | 48.6% |
| Perfect (PERF) | $1.88 | $3.63 | 48.2% |
| Investar Holding (ISTR) | $22.83 | $45.29 | 49.6% |
| Hess Midstream (HESM) | $34.41 | $66.78 | 48.5% |
| HCI Group (HCI) | $193.48 | $376.13 | 48.6% |
| First Commonwealth Financial (FCF) | $16.81 | $32.97 | 49% |
| First Busey (BUSE) | $23.17 | $45.30 | 48.8% |
| Alnylam Pharmaceuticals (ALNY) | $456.35 | $884.81 | 48.4% |
| AGNC Investment (AGNC) | $10.06 | $19.36 | 48% |
We're going to check out a few of the best picks from our screener tool.
Bank First (BFC)
Overview: Bank First Corporation, with a market cap of $1.26 billion, operates as a holding company for Bank First, N.A., providing various banking services.
Operations: The company generates revenue primarily through its banking operations, amounting to $166 million.
Estimated Discount To Fair Value: 10.6%
Bank First is trading at US$128.34, below its estimated fair value of US$143.63, indicating it may be undervalued based on cash flows. The company's earnings and revenue are forecast to grow significantly faster than the US market over the next three years, with earnings expected to increase by 33.13% annually. Recent financial results show improved net interest income and net income compared to last year, alongside a share buyback program enhancing shareholder value.
- The analysis detailed in our Bank First growth report hints at robust future financial performance.
- Get an in-depth perspective on Bank First's balance sheet by reading our health report here.
BioLife Solutions (BLFS)
Overview: BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy industry across various regions, with a market cap of approximately $1.27 billion.
Operations: The company's revenue is primarily derived from its Biopreservation Tools segment, which generated $93.47 million.
Estimated Discount To Fair Value: 37.3%
BioLife Solutions, trading at US$26.59, is significantly below its estimated fair value of US$42.4, highlighting its potential undervaluation based on cash flows. Despite recent insider selling, the company forecasts revenue growth faster than the US market and expects to become profitable within three years. Recent earnings guidance was revised upward for 2025, reflecting strong performance in their Cell Processing platform with expected revenue growth between 22% and 25% compared to last year.
- Our earnings growth report unveils the potential for significant increases in BioLife Solutions' future results.
- Navigate through the intricacies of BioLife Solutions with our comprehensive financial health report here.
Palomar Holdings (PLMR)
Overview: Palomar Holdings, Inc. is a specialty insurance company offering property and casualty insurance to individuals and businesses in the United States, with a market cap of approximately $3.12 billion.
Operations: The company generates revenue of $682.21 million from its property and casualty insurance business in the United States.
Estimated Discount To Fair Value: 44.6%
Palomar Holdings, priced at US$116.57, is trading significantly below its estimated fair value of US$210.53, suggesting potential undervaluation based on cash flows. Recent earnings reports show robust growth with Q2 revenue reaching US$203.31 million and net income at US$46.53 million, both up from last year. Despite substantial insider selling recently, the company forecasts annual revenue growth of 21%, outpacing the broader market's 9.8% projection.
- According our earnings growth report, there's an indication that Palomar Holdings might be ready to expand.
- Click here and access our complete balance sheet health report to understand the dynamics of Palomar Holdings.
Where To Now?
- Get an in-depth perspective on all 201 Undervalued US Stocks Based On Cash Flows by using our screener here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Looking For Alternative Opportunities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if BioLife Solutions might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:BLFS
BioLife Solutions
Develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
Flawless balance sheet with reasonable growth potential.
Market Insights
Weekly Picks

From a “Shark Tank” Snub to an Air Force “Yes”: Why Virtuix at $3.50 May Be the Market’s Most Mispriced AI Story

Mastercard: The Best Dividend Stock You're Ignoring

A Wonderful Business at a Not-So-Wonderful Price

The Asymmetric TechBio Play: MindWalk Holdings and the Valuation Disconnect
Recently Updated Narratives

Abitibi Metals’ High-Grade B26 Polymetallic Deposit Trading at a Fraction of Peers, 96% Undervalued?
Zylox-Tonbridge: Early Signs of an Emerging Global Vascular Intervention Platform
Geohan's Growth Outlook Brightens on Expanding Order Book and Easing Cost Pressures
Popular Narratives

Mastercard: The Best Dividend Stock You're Ignoring

Adobe: A Probabilistic Case for Undervaluation

